Mar 21, 2022 8:30am EDT Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update
Mar 02, 2022 8:30am EST Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol
Jan 12, 2022 8:30am EST Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update
Jan 11, 2022 8:30am EST Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom
Jan 10, 2022 9:00am EST Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference
Nov 29, 2021 8:30am EST Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update
Sep 08, 2021 8:30am EDT Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 11, 2021 7:30am EDT Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th
Aug 04, 2021 8:30am EDT Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines
